Investor Presentation
M&A accelerates our expansion, elevates our presence
Our strategic acquisitions meet strict criteria:
o Technology leadership
o Strengthens, expands Repligen's market position
o Underinvested in a key area
o Strong revenue growth, margins in line with or
above corporate average
o Potential to be accretive to adjusted EPS in first
full yet-acquisition
2014-2019:
o Built out Filtration, established Analytics franchises
2020-2023:
o Built out Fluid Management
o Strengthening all franchises
R REPLIGEN
Areas of Investment to Accelerate Growth
Commercial Operations
Acquisition
C Technologies
May 2019
Highly differentiated, in-line, real-time, fast and accurate measurement
ARTESYN
Biosolutions
December 2020
Premier integrated systems for filtration and chromatography
Polymem S.A.
June 2021
World class hollow-fiber; immediately expanded HF capacity 3x-4x
Avitide Inc.
Sept. 2021
Analytics
R&D
Leading-edge content player; largest most diverse ligand library, gene-
therapy affinity resin focus
Filtration
Chromatography
Proteins & Affinity Resins
14View entire presentation